(Q44202984)

30 November 2017

title

The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia (English)

1 reference

30 November 2017

0 references

Karu Jayathilake

1 reference

30 November 2017

Tomiki Sumiyoshi

1 reference

30 November 2017

Herbert Y Meltzer

series ordinal

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

30 November 2017

published in

Schizophrenia Research

1 reference

30 November 2017

1 reference

30 November 2017

1 reference

30 November 2017

page(s)

7-16

1 reference

Neurocognitive and social functioning in schizophrenia

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Neurocognitive and social functioning in schizophrenia and other diagnoses.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Verbal learning and memory in schizotypal personality disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Cognitive functions in schizotypal personality disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

A diagnostic interview: the schedule for affective disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Wisconsin Card Sorting Test deficits in schizotypic individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Stability and course of neuropsychological deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Attention and higher cortical functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Risperidone versus haloperidol on secondary memory: can newer medications aid learning?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAY x 3702 in freely moving rats

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Regional cerebral blood flow during the Wisconsin Card Sorting Test in normal subjects studied by xenon-133 dynamic SPECT: comparison of absolute values, percent distribution values, and covariance analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

The role of cognition in vocational functioning in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Neuropsychological change in schizophrenia after 6 weeks of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

The cognitive efficacy of atypical antipsychotics in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Processing of context information in schizophrenia: relation to clinical symptoms and WCST performance

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Plasma homovanillic acid in the prodromal phase of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

Changes in regional cerebral blood flow due to cognitive activation among patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900329-2

7 January 2021

10.1016/S0920-9964(01)00329-2

Identifiers

DOI

1 reference

30 November 2017

1 reference